术前肌少症与胰腺癌患者胰十二指肠切除术后总生存期不良相关
该回顾性研究纳入2005年10月至2018年8月间116例接受胰十二指肠切除术的胰腺腺癌患者,基于术前L3层面CT测量腹部体成分,分析其与生存的关系。结果显示术前肌少症和肌少症性肥胖与更短的总生存期相关,肌少症是总生存期的唯一显著预后因素,但与无病生存期无关。
要点
- 术前L3层面CT可评估肌少症和肌少症性肥胖,肌少症与胰腺癌术后总生存期不良相关。
- 肌少症是总生存期的唯一显著预后因素,但与无病生存期无关。
- 肌少症性肥胖与更短总生存期相关,肌脂肪变性则与无病生存期和总生存期均无关。
核心结论
- 术前CT评估的肌少症是胰腺癌患者胰十二指肠切除术后总生存期的不良预后因素。
- 术前肌少症和肌少症性肥胖与更短的总生存期相关,但与无病生存期无关。
- 肌脂肪变性既与无病生存期无关,也与总生存期无关。
研究设计与样本
- 回顾性研究,纳入2005年10月至2018年8月间116例(男68例,女48例,平均年龄66.2±11.9岁)接受胰十二指肠切除术的胰腺腺癌患者。
- 术前CT于L3椎体层面测量总腹部肌肉面积(TAMA)、内脏脂肪面积(VAT)、皮下脂肪面积(SAT)和平均骨骼肌衰减(SMD)。
- 收集临床数据和肿瘤病理结果,采用Kaplan-Meier法及单变量和多变量Cox比例风险模型评估各因素对无病生存期和总生存期的影响。
诊断标准与关键数值
- 116例患者中,20例(17.2%)为肌少症,3例(2.6%)为肌少症性肥胖,46例(39.7%)为肌脂肪变性。
- 肌少症组VAT-TAMA比值为1.2±0.7,非肌少症组为0.9±0.5(p=0.01)。
- 肌少症组内脏脂肪与皮下脂肪面积比值为1.3±0.7,非肌少症组为0.9±0.5(p=0.04)。
- 术前肌少症与更短总生存期相关(p=0.012),肌少症性肥胖与更短总生存期相关(p=0.041)。
- 多变量分析中,肌少症是总生存期的唯一显著预后因素(p=0.039)。
临床应用与阅片要点
- 腹部CT于L3层面可评估肌少症和肌少症性肥胖,阅片时可关注骨骼肌面积和衰减。
- 糖尿病患者的性别标准化皮下脂肪面积指数和骨骼肌密度较低,内脏脂肪与皮下脂肪面积比值较高。
- 术前肌少症、肌少症性肥胖和新发糖尿病可能预测胰十二指肠切除术后总生存期不良,作者在结论中提出此可能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To analyze the effect of preoperative body composition on survival in patients with pancreatic cancer following pancreaticoduodenectomy (PD).
METHODS: Between October 2005 and August 2018, 116 patients (68 men, 48 women, mean age 66.2 ± 11.9 years) diagnosed with pancreatic adenocarcinoma following PD were retrospectively enrolled. The preoperative CT on vertebral level L3 was assessed for total abdominal muscle area (TAMA), visceral adipose tissue area (VAT), subcutaneous adipose tissue area (SAT), and mean skeletal muscle attenuation (SMD). The clinical data and pathological findings of tumors were collected. The impact of these factors on disease-free survival (DFS) and overall survival (OS) was evaluated by the Kaplan-Meier method and by univariable and multivariable Cox proportional hazards models.
RESULTS: The 3-year DFS and OS rates were 8% and 25%, respectively. Of 116 patients, 20 (17.2%), 3 (2.6%), and 46 (39.7%) patients were classified as having sarcopenia, sarcopenic obesity, and myosteatosis, respectively. The VAT-TAMA ratio (1.2 ± 0.7 vs 0.9 ± 0.5, p = 0.01) and the visceral to subcutaneous adipose tissue area ratio (1.3 ± 0.7 vs 0.9 ± 0.5, p = 0.04) were higher in sarcopenic patients than in the nonsarcopenic group. Preoperative sarcopenia and sarcopenic obesity were associated with shorter OS (p = 0.012 and p = 0.041, respectively), but not shorter DFS. Myosteatosis was neither associated with DFS nor OS. On multivariable analysis, sarcopenia was the only significant prognostic factor for OS (p = 0.039).
CONCLUSIONS: Preoperative sarcopenia assessed by CT is a poor prognostic factor for OS in pancreatic cancer patients after PD.
KEY POINTS: • Sarcopenia and sarcopenic obesity can be evaluated by abdominal CT on L3 level. • Patients with diabetes mellitus (DM) had lower sex-standardized subcutaneous adipose tissue area index and skeletal muscle density and higher visceral to subcutaneous adipose tissue area ratio than did those without DM. • Preoperative sarcopenia, sarcopenic obesity, and new-onset diabetes mellitus may predict poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy.
引用
- Peng YC, Wu CH, Tien YW, et al. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy. Eur Radiol. 2020. PMID: 32974690. doi:10.1007/s00330-020-07294-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。